Oncolytics Biotech (TSE:ONC – Get Free Report) had its target price hoisted by stock analysts at Raymond James from C$3.00 to C$3.50 in a report released on Friday, BayStreet.CA reports. Raymond James’ price target suggests a potential upside of 177.78% from the stock’s current price.
Oncolytics Biotech Stock Performance
ONC traded down C$0.03 on Friday, hitting C$1.26. The company had a trading volume of 58,321 shares, compared to its average volume of 54,194. Oncolytics Biotech has a 1-year low of C$1.20 and a 1-year high of C$3.10. The company’s fifty day moving average price is C$1.35 and its 200 day moving average price is C$1.42. The stock has a market cap of C$96.84 million, a price-to-earnings ratio of -3.34 and a beta of 1.38. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86.
Oncolytics Biotech (TSE:ONC – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported C($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of C($0.10). Equities analysts predict that Oncolytics Biotech will post -0.41 earnings per share for the current fiscal year.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Recommended Stories
- Five stocks we like better than Oncolytics Biotech
- What Are Growth Stocks and Investing in Them
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Bank Stocks – Best Bank Stocks to Invest In
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.